Mark Enyedy, ImmunoGen CEO
May 3, 2023 11:22 AM EDTUpdated 02:28 PM
R&D

Im­muno­Gen’s ovar­i­an can­cer treat­ment helps pa­tients live longer than chemo in con­fir­ma­to­ry tri­al

Lei Lei Wu

News Reporter

In No­vem­ber, the FDA grant­ed ac­cel­er­at­ed ap­proval to Im­muno­Gen’s drug Ela­here for ad­vanced ovar­i­an can­cer — the first new treat­ment for the dis­ease in at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times